Monopar Therapeutics Inc.
1000
Skokie Blvd., Suite 350
Wilmette,
Illinois 60091
September
30, 2019
VIA EDGAR
US
Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, NE
Washington,
DC 20549
Re:
Monopar Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-233303
Ladies
and Gentlemen:
Pursuant to Rule
461 under the Securities Act of 1933, as amended, Monopar
Therapeutics Inc. (the “Company”) hereby respectfully
requests that the above-referenced Registration Statement be
declared effective at 4 p.m., Eastern time, on October 2, 2019 or
as soon thereafter as practicable, or such later time as the
Company or its counsel may orally request via telephone call to the
staff of the Division of Corporation Finance.
Please
contact John Harrington of
Baker & Hostetler LLP at (216) 861-6697 with any
questions regarding the foregoing and to confirm the effectiveness
of the Registration Statement.
Very truly
yours,
|
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
|
|
By:
|
/s/
Chandler D.
Robinson
|
|
|
|
|
Name: Chandler D.
Robinson
|
|
|
|
|
Title:
Chief Executive
Officer
|
|